|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 104.80 EUR | +0.58% |
|
-2.87% | +1.26% |
| 12-04 | BioMérieux Launches Two Dedicated Equine Tests | |
| 11-10 | UBS Maintains Buy Rating on BioMérieux, Confirms Price Target |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 404M | 601M | 452M | 358M | 432M | |||||
Depreciation & Amortization - CF | 160M | 172M | 147M | 196M | 242M | |||||
Amortization of Goodwill and Intangible Assets - (CF) | 48.4M | 59.4M | 82.7M | 122M | 102M | |||||
Depreciation & Amortization, Total | 209M | 231M | 230M | 318M | 344M | |||||
Amortization of Deferred Charges, Total - (CF) | 19.6M | 16.9M | 18.1M | 15.7M | 16.3M | |||||
(Gain) Loss on Sale of Investments - (CF) | 600K | -600K | - | - | - | |||||
Asset Writedown & Restructuring Costs | 17.5M | 16.9M | 29M | 130M | 22.9M | |||||
(Income) Loss On Equity Investments - (CF) | 200K | 700K | - | - | - | |||||
Stock-Based Compensation (CF) | 9.9M | 12.4M | 13M | 19.7M | 23.4M | |||||
Other Operating Activities, Total | 2.5M | -30.8M | -111M | -192M | -121M | |||||
Change In Accounts Receivable | -80.4M | 23.6M | -146M | -13.7M | -53.7M | |||||
Change In Inventories | -82.9M | -62.4M | -92.1M | -193M | -85.1M | |||||
Change In Accounts Payable | 4.7M | 24.2M | 9.9M | 3.4M | -600K | |||||
Change in Other Net Operating Assets | 77.9M | -21.8M | 71.9M | -400K | 88.4M | |||||
Cash from Operations | 583M | 811M | 475M | 445M | 667M | |||||
Capital Expenditure | -278M | -290M | -287M | -338M | -346M | |||||
Sale of Property, Plant, and Equipment | 24.7M | 20M | 17.4M | 6.4M | 9.4M | |||||
Cash Acquisitions | -10.1M | -36.8M | -205M | - | -8.8M | |||||
Divestitures | - | - | - | - | - | |||||
Investment in Marketable and Equity Securities, Total | -2.3M | -400K | -53.8M | -157M | -14.6M | |||||
Cash from Investing | -265M | -307M | -528M | -489M | -360M | |||||
Long-Term Debt Issued, Total | 292M | 18.2M | 67.7M | 38.9M | 9.8M | |||||
Total Debt Issued | 292M | 18.2M | 67.7M | 38.9M | 9.8M | |||||
Long-Term Debt Repaid, Total | -426M | -68.3M | -53.4M | -73.7M | -84.6M | |||||
Total Debt Repaid | -426M | -68.3M | -53.4M | -73.7M | -84.6M | |||||
Issuance of Common Stock | - | - | - | 12.7M | - | |||||
Repurchase of Common Stock | -18.4M | -3.8M | -157M | - | -37.6M | |||||
Common Dividends Paid | -22.5M | -73.1M | -101M | -100M | - | |||||
Common & Preferred Stock Dividends Paid | -22.5M | -73.1M | -101M | -100M | - | |||||
Other Financing Activities, Total | -800K | - | -100K | - | -100M | |||||
Cash from Financing | -176M | -127M | -244M | -122M | -213M | |||||
Foreign Exchange Rate Adjustments | -34.1M | 39.2M | 38.7M | -29.7M | 13.9M | |||||
Miscellaneous Cash Flow Adjustments | - | - | - | 100K | - | |||||
Net Change in Cash | 107M | 416M | -258M | -195M | 109M | |||||
Supplemental Items | ||||||||||
Cash Interest Paid | 24.9M | 9.1M | 4.1M | 4.4M | 16M | |||||
Cash Income Tax Paid (Refund) | 116M | 185M | 224M | 204M | 206M | |||||
Levered Free Cash Flow | 283M | 395M | 168M | 159M | 298M | |||||
Unlevered Free Cash Flow | 298M | 401M | 170M | 162M | 308M | |||||
Change In Net Working Capital | 45.4M | 70.1M | 187M | 209M | 129M | |||||
Net Debt Issued / Repaid | -134M | -50.1M | 14.3M | -34.8M | -74.8M |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















